Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis

Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis

Inactivated coronavirus disease 2019 (COVID-19) vaccines showed impaired immunogenicity in some autoimmune diseases, but it remains unclear in primary biliary cholangitis (PBC). This study aimed to explore the antibody response to the inactivated COVID-19 vaccine in individuals with PBC, as well as...

Full description

Bibliographic Details
Main Authors: Haolong Li, Xu Wang, Siyu Wang, Xinxin Feng, Li Wang, Yongzhe Li
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Heliyon
Subjects:
Primary biliary cholangitis
COVID-19
Antibody
Vaccine
Immune response
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024044360

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024044360

Similar Items